Pancreatic neuroendocrine tumours account for <2% of all cancers arising in the pancreas.[6]Camera L, Severino R, Faggiano A, et al. Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma. World J Radiol. 2014 Oct 28;6(10):840-5.
https://www.doi.org/10.4329/wjr.v6.i10.840
http://www.ncbi.nlm.nih.gov/pubmed/25349667?tool=bestpractice.com
Epidemiological data for specific types of neuroendocrine tumours are scant. In the US, the incidence rate of pancreatic neuroendocrine tumours has risen from 0.27 to 1.00 per 100,000 persons from 2000 to 2016 (based on Surveillance, Epidemiology, and End Results [SEER] data). This increase has been attributed to improved diagnostic techniques and increased detection of localised disease.[7]Sonbol MB, Mazza GL, Mi L, et al. Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: a SEER database analysis. Oncologist. 2022 Jul 5;27(7):573-8.
https://academic.oup.com/oncolo/article/27/7/573/6555099
http://www.ncbi.nlm.nih.gov/pubmed/35348774?tool=bestpractice.com
Modest data suggest that men and women are equally affected by neuroendocrine tumours, including VIPoma.[8]Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-42.
https://www.doi.org/10.1001/jamaoncol.2017.0589
http://www.ncbi.nlm.nih.gov/pubmed/28448665?tool=bestpractice.com
[9]Ghaferi AA, Chojnacki KA, Long WD, et al. Pancreatic VIPomas: subject review and one institutional experience. J Gastointest Surg. 2008 Feb;12(2):382-93.
http://www.ncbi.nlm.nih.gov/pubmed/17510774?tool=bestpractice.com
Median age at diagnosis of 51 years (range 11-75 years) has been derived from individual case reports.[9]Ghaferi AA, Chojnacki KA, Long WD, et al. Pancreatic VIPomas: subject review and one institutional experience. J Gastointest Surg. 2008 Feb;12(2):382-93.
http://www.ncbi.nlm.nih.gov/pubmed/17510774?tool=bestpractice.com